Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$123K Sell
1,847
-2,194
-54% -$142K 0.12% 96
2025
Q3
$272K Hold
4,041
0.1% 97
2025
Q2
$353K Buy
4,041
+211
+6% +$16.5K 0.14% 97
2025
Q1
$262K Buy
3,830
+277
+8% +$22.6K 0.13% 95
2024
Q4
$276K Sell
3,553
-2,038
-36% -$151K 0.12% 95
2024
Q3
$375K Sell
5,591
-600
-10% -$49.3K 0.17% 90
2024
Q2
$702K Sell
6,191
-296
-5% -$37.4K 0.3% 67
2024
Q1
$900K Buy
6,487
+41
+0.6% +$5.15K 0.39% 60
2023
Q4
$800K Buy
6,446
+67
+1% +$6.84K 0.38% 60
2023
Q3
$595K Buy
6,379
+3,920
+159% +$442K 0.32% 73
2023
Q2
$316K Sell
2,459
-1,908
-44% -$231K 0.34% 55
2023
Q1
$507K Buy
4,367
+1,787
+69% +$200K 0.34% 62
2022
Q4
$292K Buy
+2,580
New +$283K 0.42% 53

Other funds holding DXCM

STF Management's DXCM Position: Q4 2025 in Review

STF Management reduced its DexCom (DXCM) stake by 54% in Q4 2025, selling an estimated $142K and leaving 1,847 shares worth $123K. The position accounts for 0.12% of the portfolio, ranked #96.

STF Management first reported a position in DXCM in Q4 2022 and has held it in 13 quarters since. The position peaked at $900K in Q1 2024. 920 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

  • STF Management held 1,847 shares of DexCom worth $123K as of Q4 2025.
  • STF Management sold 2,194 DexCom shares in Q4 2025, an estimated $142K.
  • DexCom made up 0.12% of STF Management's portfolio in Q4 2025, its #96 holding.
  • STF Management first reported a position in DexCom in Q4 2022 and has held it in 13 quarters since.
  • STF Management's DexCom position peaked at $900K in Q1 2024.
  • 920 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on STF Management's 13F filing for Q4 2025, filed 5 Feb 2026.